YDES

+ Watchlist + Portfolio

YD Bio Limited

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $7.81
52-Week Range: $1.70 – $22.00
Market Cap: $574.44M
P/E (TTM): —
EPS (TTM): -0.04
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.77
PEG Ratio: —
Return on Equity: —
Return on Assets: —
Gross Margin: 29.60%
Operating Margin: -382.12%
Profit Margin: 24.67%
Current Ratio: 5.23
Debt/Equity: 0.00
Total Debt: $5.00K
Free Cash Flow: —
Revenue Growth: 314.90%
Earnings Growth: —
Enterprise Value: $571.88M

YDES Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Revenue	$350.13K	$510.36K	$596.82K
Cost of Revenue	$196.69K	$355.00K	$429.41K
Gross Profit	$153.44K	$155.36K	$167.41K
Research & Development	$0.00	$491.35K	$1.60M
Selling, General & Admin	$160.56K	$1.12M	$3.82M
Operating Expenses	$160.56K	$1.62M	$5.44M
Operating Income	-$7.12K	-$1.46M	-$5.27M
EBITDA	$22.25K	-$1.28M	-$8.10M
Pretax Income	$17.65K	-$1.39M	-$8.31M
Income Tax	$4.09K	$25.08K	-$1.53K
Net Income	$13.56K	-$1.41M	-$8.31M
Diluted EPS	0.00	-0.02	-0.12
Diluted Shares	70.10M	70.10M	66.72M

YDES Balance Sheet statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Cash & Equivalents	$87.10K	$3.13M	$6.01M
Receivables	$98.43K	$262.80K	$712.26K
Inventory	$69.40K	$37.34K	$1.88M
Current Assets	$271.72K	$3.47M	$9.67M
Total Assets	$321.21K	$6.86M	$13.78M
Current Liabilities	$298.22K	$263.06K	$1.64M
Total Debt	$47.58K	$22.27K	$6.76K
Total Liabilities	$298.22K	$273.98K	$16.64M
Retained Earnings	-$515.48K	-$1.93M	-$10.24M
Shareholders' Equity	$22.99K	$6.59M	-$2.86M
Working Capital	-$26.49K	$3.20M	$8.03M

YDES Cash Flow statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Operating Cash Flow	-$55.66K	-$1.22M	-$6.60M
Capital Expenditure	-$290.00	-$2.91M	-$1.44M
Free Cash Flow	-$55.95K	-$4.13M	-$8.04M
Depreciation & Amortisation	$2.45K	$104.73K	$209.56K
Investing Cash Flow	-$290.00	-$2.90M	-$1.44M
Financing Cash Flow	$113.89K	$7.11M	$10.87M
Net Change in Cash	$57.94K	$2.99M	$2.83M

YDES Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q4 2025	Q2 2026
Cash & Equivalents	$469.52K	$6.01M	$2.66M
Receivables	$386.69K	$712.26K	$558.86K
Inventory	$373.52K	$1.88M	$1.89M
Current Assets	$1.40M	$9.67M	$5.59M
Total Assets	$5.84M	$13.78M	$10.06M
Current Liabilities	$752.93K	$1.64M	$1.07M
Total Debt	$16.61K	$6.76K	$5.00K
Total Liabilities	$752.93K	$16.64M	$5.59M
Retained Earnings	-$3.84M	-$10.24M	-$3.54M
Shareholders' Equity	$5.09M	-$2.86M	$4.47M
Working Capital	$643.91K	$8.03M	$4.52M

Market Snapshot

About

YD Bio Limited is a biotechnology company engaged in the research, development, and commercialization of pharmaceutical and biological products. The company focuses on developing treatments for various medical conditions using advanced biological science and drug development technologies. YD Bio operates primarily in the biopharmaceutical sector with a focus on innovative therapeutics.